We hosted a series of online “RNAi Roundtables” during July and August, at which Alnylam scientists and key clinical collaborators reviewed recent progress from several “Alnylam 5×15” programs and discussed the related disease areas.
These are exciting times for RNAi therapeutics. Important scientific and clinical advancements are being made at a very rapid pace. The discovery of RNAi has been widely acknowledged as a major breakthrough in biology, and the belief that this technology has the potential to make a broad and significant impact in medicine is stronger than ever. Alnylam is leading the effort in translating the science of RNAi into a sustainable product pipeline of innovative medicines.
At Alnylam, we are unwavering in our commitment to scientific excellence, and we are driven by our dedication to the highest scientific standards. A testament to this underlying tenet at Alnylam is the publication of our research in world-leading, peer-reviewed scientific journals, such as Nature, Nature Medicine, Nature Biotechnology, Cell, New England Journal of Medicine, and The Lancet, amongst others. We believe our numerous publications – numbering over 200 to date – and collaborations with some of the world’s best research labs are important measures of our position as the scientific and clinical leaders in the RNAi
field. Our scientific and clinical papers also serve to demonstrate to leading academic scientists, clinicians, and pharmaceutical executives the potential impact of our discoveries and the opportunity for RNAi therapeutics to become a new therapeutic approach in medicine, in addition to Alnylam’s commitment to and leadership in translating and advancing the field.